Hrt Financial LP Morpho Sys Ag Transaction History

Hrt Financial LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$4.51 - $7.39 $205,042 - $335,978	-45,464 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.87 - $9.73 $213,474 - $353,850	-36,367 Reduced 44.44%	45,464 $308,000
Q4 2021 Feb 14, 2022	BUY	$9.08 - $12.45 $631,750 - $866,221	69,576 Added 567.74%	81,831 $770,000
Q3 2021 Nov 15, 2021	BUY	$11.76 - $19.51 $23,543 - $39,059	2,002 Added 19.53%	12,255 $144,000
Q2 2021 Aug 16, 2021	BUY	$18.95 - $23.95 $194,294 - $245,559	10,253 New	10,253 $197,000

11.3M

320K

1.1M

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Market Cap $2.47B
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.